{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:50:16Z","timestamp":1780469416096,"version":"3.54.1"},"reference-count":75,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,12,15]],"date-time":"2016-12-15T00:00:00Z","timestamp":1481760000000},"content-version":"vor","delay-in-days":2389,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","hpbonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["HPB"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1111\/j.1477-2574.2010.00183.x","type":"journal-article","created":{"date-parts":[[2015,10,13]],"date-time":"2015-10-13T10:13:57Z","timestamp":1444731237000},"page":"313-320","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"title":["Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement"],"prefix":"10.1016","volume":"12","author":[{"given":"Roderich E.","family":"Schwarz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghassan K.","family":"Abou-Alfa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey F.","family":"Geschwind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riad","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan P.","family":"Venook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0010","first-page":"225","article-title":"Cancer statistics, 2009","volume":"59","author":"Jemal","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0015","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.amjsurg.2007.10.010","article-title":"Trends in local therapy for hepatocellular carcinoma and survival outcomes in the US population","volume":"195","author":"Schwarz","year":"2008","journal-title":"Am J Surg"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0020","first-page":"81","article-title":"Hepatic artery embolization in 32 patients with unresectable hepatoma","volume":"26","author":"Yamada","year":"1980","journal-title":"Osaka City Med J"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0025","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1148\/radiology.148.2.6306721","article-title":"Hepatic artery embolization in 120 patients with unresectable hepatoma","volume":"148","author":"Yamada","year":"1983","journal-title":"Radiology"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0030","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/1097-0142(19831215)52:12<2193::AID-CNCR2820521203>3.0.CO;2-R","article-title":"Studies on anticancer treatment with an oily anticancer drug injected into the ligated feeding hepatic artery for liver cancer","volume":"52","author":"Nakakuma","year":"1983","journal-title":"Cancer"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0035","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/0277-5379(83)90028-7","article-title":"Effect of arterial administration of high-molecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report","volume":"19","author":"Konno","year":"1983","journal-title":"Eur J Cancer Clin Oncol"},{"issue":"3","key":"10.1111\/j.1477-2574.2010.00183.x_bb0040","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1159\/000201208","article-title":"Hepatic arterial chemoembolization for metastatic neuroendocrine tumors","volume":"55","author":"Clouse","year":"1994","journal-title":"Digestion"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0045","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1053\/j.gastro.2004.09.032","article-title":"Chemoembolization for hepatocellular carcinoma","volume":"127","author":"Bruix","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0050","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1007\/BF00687096","volume":"31","author":"Kawai","year":"1992","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0055","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1002\/1097-0142(19941101)74:9<2449::AID-CNCR2820740910>3.0.CO;2-4","article-title":"Transcatheter arterial embolization with or without cisplatin treatment of hepatocellular carcinoma. A randomized controlled study","volume":"74","author":"Chang","year":"1994","journal-title":"Cancer"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0060","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00270-002-2524-6","article-title":"Transcatheter arterial chemoembolization of liver tumors: effects of embolization protocol on injectable volume of chemotherapy and subsequent arterial patency","volume":"26","author":"Geschwind","year":"2003","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0065","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00270-001-0070-2","article-title":"Accumulation of iodized oil within the nonneoplastic liver adjacent to hepatocellular carcinoma via the drainage routes of the tumor after transcatheter arterial embolization","volume":"24","author":"Terayama","year":"2001","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0070","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1002\/bjs.1800811105","article-title":"Iodized oil in the treatment of hepatocellular carcinoma","volume":"81","author":"Bhattacharya","year":"1994","journal-title":"Br J Surg"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0075","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","article-title":"Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial","volume":"359","author":"Llovet","year":"2002","journal-title":"Lancet"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0080","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1056\/NEJM199505113321903","article-title":"A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma","volume":"332","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0085","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","article-title":"Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma","volume":"35","author":"Lo","year":"2002","journal-title":"Hepatology"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0090","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1001\/archsurg.139.7.766","article-title":"Sequential preoperative arterial and portal venous embolizations in patients with hepatocellular carcinoma","volume":"139","author":"Aoki","year":"2004","journal-title":"Arch Surg"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0095","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(03)14964-1","article-title":"Hepatocellular carcinoma","volume":"362","author":"Llovet","year":"2003","journal-title":"Lancet"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0100","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s11938-004-0002-8","article-title":"Treatment of Hepatocellular Carcinoma","volume":"7","author":"Llovet","year":"2004","journal-title":"Curr Treat Options Gastroenterol"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0105","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1053\/j.gastro.2006.05.021","article-title":"Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients","volume":"131","author":"Takayasu","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0110","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1002\/lt.20053","article-title":"Multimodal image-guided tailored therapy of early and intermediate hepatocellular carcinoma: long-term survival in the experience of a single radiologic referral center","volume":"10","author":"Livraghi","year":"2004","journal-title":"Liver Transpl"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0115","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1097\/01.RVI.0000236608.91960.34","article-title":"Prognostic accuracy of 12 liver staging systems in patients with unresectable hepatocellular carcinoma treated with transarterial chemoembolization","volume":"17","author":"Georgiades","year":"2006","journal-title":"J Vasc Interv Radiol"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0120","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/hep.510270617","article-title":"Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution","volume":"27","author":"Bruix","year":"1998","journal-title":"Hepatology"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0125","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/01.RVI.0000147068.25548.57","article-title":"Case-controlled comparison of a percutaneous collagen arteriotomy closure device versus manual compression after liver chemoembolization","volume":"16","author":"Hong","year":"2005","journal-title":"J Vasc Interv Radiol"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0130","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/j.tvir.2007.08.008","article-title":"Transcatheter arterial chemoembolization: current technique and future promise","volume":"10","author":"Liapi","year":"2007","journal-title":"Tech Vasc Interv Radiol"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0135","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1200\/JCO.2006.09.8657","article-title":"Transcatheter and ablative therapeutic approaches for solid malignancies","volume":"25","author":"Liapi","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0140","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1053\/j.tvir.2008.03.003","article-title":"Drug-eluting particles for interventional pharmacology","volume":"10","author":"Liapi","year":"2007","journal-title":"Tech Vasc Interv Radiol"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0145","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1148\/radiol.2502072222","article-title":"Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging","volume":"250","author":"Kamel","year":"2009","journal-title":"Radiology"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0150","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1097\/01.RVI.0000182185.47500.7A","article-title":"Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis","volume":"16","author":"Georgiades","year":"2005","journal-title":"J Vasc Interv Radiol"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0155","unstructured":"Sorafenib.http:\/\/www.fda.gov\/AboutFDA\/CentersOffices\/CDER\/ucm129234.htm"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0160","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0165","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2005.01.3441","article-title":"Phase II study of sorafenib in patients with advanced hepatocellular carcinoma","volume":"24","author":"Abou-Alfa","year":"2006","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1111\/j.1477-2574.2010.00183.x_bb0170","first-page":"viii178","article-title":"Tumor necrosis as a correlate for response in subgroup of patients with advanced hepatocellular carcinoma (HCC) rreated with sorafenib","volume":"19","author":"Abou-Alfa","year":"2008","journal-title":"Ann Oncol (Abstract 547P)"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0175","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2008.18.8151","article-title":"New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy","volume":"27","author":"Chan","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0180","doi-asserted-by":"crossref","first-page":"4518","DOI":"10.1200\/jco.2008.26.15_suppl.4518","article-title":"Is sorafenib safe and effective in patients with hepatocellular carcinoma and Child-Pugh B cirrhosis?","volume":"26","author":"Abou-Alfa","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0185","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1349-7006.2007.00648.x","article-title":"Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma","volume":"99","author":"Furuse","year":"2008","journal-title":"Cancer Sci"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0190","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1200\/JCO.2008.20.0931","article-title":"Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301","volume":"27","author":"Miller","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0195","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0200","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1038\/sj.onc.1204372","article-title":"Sustained activation of the Raf\/MEK\/Erk pathway in response to EGF in stable cell lines expressing the Hepatitis C Virus (HCV) core protein","volume":"20","author":"Giambartolomei","year":"2001","journal-title":"Oncogene"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0205","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1200\/JCO.2007.15.9947","article-title":"Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma","volume":"26","author":"Siegel","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0210","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1200\/JCO.2005.04.9130","article-title":"Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma","volume":"24","author":"Zhu","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0215","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1200\/jco.2007.25.18_suppl.4574","article-title":"Combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma (HCC): A phase II study","volume":"25","author":"Sun","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0220","doi-asserted-by":"crossref","first-page":"15190","DOI":"10.1200\/jco.2007.25.18_suppl.15190","article-title":"Modified-dose capecitabine + bevacizumab for the treatment of advanced\/metastatic hepatocellular carcinoma (HCC): A phase II, single-arm study","volume":"25","author":"Hsu","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0225","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1200\/JCO.2008.18.3301","article-title":"Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma","volume":"27","author":"Thomas","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0230","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1200\/JCO.2008.20.9908","article-title":"Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study","volume":"27","author":"Zhu","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0235","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/S1470-2045(09)70171-8","article-title":"Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study","volume":"10","author":"Faivre","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0240","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.1200\/jco.2009.27.15_suppl.4581","article-title":"A phase II study of ABT-869 in hepatocellular carcinoma (HCC): Interim analysis","volume":"27","author":"Toh","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0245","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1200\/jco.2009.27.15_suppl.4577","article-title":"An open-label phase II study of first- and second-line treatment with brivanib in patients with hepatocellular carcinoma (HCC)","volume":"27","author":"Raoul","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0250","doi-asserted-by":"crossref","first-page":"4849","DOI":"10.1158\/1078-0432.CCR-07-0382","article-title":"Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors","volume":"13","author":"Duran","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0255","unstructured":"Chemoembolization with or without sorafenib tosylate in treating patients with liver cancer that cannot be removed by surgery. ECOG 1208. http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01004978?term=sorafenib+tace&rank=11"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0260","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/01.rli.0000209663.00629.8a","article-title":"Effect of transcatheter hepatic arterial embolization on angiogenesis in an animal model","volume":"41","author":"Gupta","year":"2006","journal-title":"Invest Radiol"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0265","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199603143341104","article-title":"Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis","volume":"334","author":"Mazzaferro","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0270","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/jso.20609","article-title":"Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation","volume":"94","author":"Kulik","year":"2006","journal-title":"J Surg Oncol"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0275","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1111\/j.1600-6143.2009.02695.x","article-title":"A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization","volume":"9","author":"Lewandowski","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0280","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/hep.22747","article-title":"Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres","volume":"49","author":"Riaz","year":"2009","journal-title":"Hepatology"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0285","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/hep.21980","article-title":"Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis","volume":"47","author":"Kulik","year":"2008","journal-title":"Hepatology"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0290","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2009.09.006","article-title":"Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes","volume":"138","author":"Salem","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0295","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/0360-3016(93)90398-F","article-title":"Use of Veff and iso-NTCP in the implementation of dose escalation protocols","volume":"27","author":"Ten Haken","year":"1993","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0300","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1245\/s10434-007-9729-5","article-title":"Radiotherapy for hepatocellular carcinoma: an overview","volume":"15","author":"Krishnan","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0305","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1002\/cncr.21811","article-title":"Radiation therapy for hepatocellular carcinoma: from palliation to cure","volume":"106","author":"Hawkins","year":"2006","journal-title":"Cancer"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0310","doi-asserted-by":"crossref","first-page":"8739","DOI":"10.1200\/JCO.2005.01.5354","article-title":"Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies","volume":"23","author":"Ben-Josef","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0315","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.ijrobp.2006.06.015","article-title":"Feasibility and efficacy of high-dose three-dimensional-conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies\u2013mature results of the French Phase II RTF-1 trial","volume":"66","author":"Mornex","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0320","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1080\/02841860600897934","article-title":"Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase i-ii study","volume":"45","author":"Mendez Romero","year":"2006","journal-title":"Acta Oncol"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0325","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1080\/02841860600936369","article-title":"Individualized image guided iso-NTCP based liver cancer SBRT","volume":"45","author":"Dawson","year":"2006","journal-title":"Acta Oncol"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0330","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1158\/1078-0432.CCR-04-1350","article-title":"Proton beam therapy for hepatocellular carcinoma: a retrospective review of 162 patients","volume":"11","author":"Chiba","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0335","doi-asserted-by":"crossref","first-page":"S189","DOI":"10.1053\/j.gastro.2004.09.033","article-title":"High-dose proton beam radiotherapy of hepatocellular carcinoma: preliminary results of a phase II trial","volume":"127","author":"Bush","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0340","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1200\/JCO.2005.00.620","article-title":"Phase II study of radiotherapy employing proton beam for hepatocellular carcinoma","volume":"23","author":"Kawashima","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0345","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/1097-0142(19870915)60:6<1194::AID-CNCR2820600607>3.0.CO;2-T","article-title":"A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin, and gelatin sponge","volume":"60","author":"Sasaki","year":"1987","journal-title":"Cancer"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0350","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/1097-0142(19930101)71:1<62::AID-CNCR2820710111>3.0.CO;2-8","article-title":"Experience with liver resection after hepatic arterial chemoembolization for hepatocellular carcinoma","volume":"71","author":"Yu","year":"1993","journal-title":"Cancer"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0355","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0360-3016(98)00415-5","article-title":"Combined transcatheter arterial chemoembolization and local radiotherapy of unresectable hepatocellular carcinoma","volume":"43","author":"Seong","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0360","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0360-3016(00)00519-8","article-title":"Local radiotherapy for unresectable hepatocellular carcinoma patients who failed with transcatheter arterial chemoembolization","volume":"47","author":"Seong","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0365","first-page":"467","article-title":"Radiotherapy for large hepatocellular carcinoma combined with transcatheter arterial embolization and percutaneous ethanol injection therapy","volume":"15","author":"Yasuda","year":"1999","journal-title":"Int J Oncol"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0370","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1259\/bjr.73.874.11271902","article-title":"Evaluation of combined therapy with chemoembolization and irradiation for large hepatocellular carcinoma","volume":"73","author":"Guo","year":"2000","journal-title":"Br J Radiol"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0375","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/ijc.1022","article-title":"Unresectable hepatocellular carcinoma treated with radiotherapy and\/or chemoembolization","volume":"96","author":"Chia-Hsien Cheng","year":"2001","journal-title":"Int J Cancer"},{"key":"10.1111\/j.1477-2574.2010.00183.x_bb0380","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/cncr.23684","article-title":"Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis","volume":"113","author":"Han","year":"2008","journal-title":"Cancer"}],"container-title":["HPB"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1365182X15303002?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1365182X15303002?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T23:53:26Z","timestamp":1761263606000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1365182X15303002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":75,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["S1365182X15303002"],"URL":"https:\/\/doi.org\/10.1111\/j.1477-2574.2010.00183.x","relation":{},"ISSN":["1365-182X"],"issn-type":[{"value":"1365-182X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement","name":"articletitle","label":"Article Title"},{"value":"HPB","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/j.1477-2574.2010.00183.x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 International Hepato-Pancreato-Biliary Association. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}